Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference
Revelation Biosciences (NASDAQ: REVB), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, has announced its participation in the 37th Annual Roth Conference. James Rolke, the company's Chief Executive Officer, will engage in a fireside chat scheduled for Tuesday, March 18, 2025 at 10:00 a.m. PT in Dana Point, CA.
The event will be accessible through a live webcast and will subsequently be available for viewing in the Investors section of Revelation's website at www.RevBiosciences.com. Interested investors can arrange meetings with the management team through their Roth representatives.
Revelation Biosciences (NASDAQ: REVB), un'azienda di scienze della vita in fase clinica focalizzata sul riequilibrio dell'infiammazione per ottimizzare la salute, ha annunciato la sua partecipazione al 37° Annual Roth Conference. James Rolke, Amministratore Delegato dell'azienda, parteciperà a una chiacchierata informale programmata per martedì 18 marzo 2025 alle 10:00 a.m. PT a Dana Point, CA.
L'evento sarà accessibile tramite una diretta web e successivamente sarà disponibile per la visione nella sezione Investitori del sito web di Revelation all'indirizzo www.RevBiosciences.com. Gli investitori interessati possono organizzare incontri con il team di gestione tramite i loro rappresentanti Roth.
Revelation Biosciences (NASDAQ: REVB), una empresa de ciencias de la vida en etapa clínica centrada en reequilibrar la inflamación para optimizar la salud, ha anunciado su participación en la 37ª Conferencia Anual Roth. James Rolke, el Director Ejecutivo de la empresa, participará en una charla informal programada para el martes 18 de marzo de 2025 a las 10:00 a.m. PT en Dana Point, CA.
El evento será accesible a través de una transmisión en vivo y posteriormente estará disponible para su visualización en la sección de Inversores del sitio web de Revelation en www.RevBiosciences.com. Los inversores interesados pueden organizar reuniones con el equipo de gestión a través de sus representantes de Roth.
Revelation Biosciences (NASDAQ: REVB)는 건강을 최적화하기 위해 염증의 균형을 재조정하는 데 초점을 맞춘 임상 단계 생명 과학 회사로, 제37회 연례 로스 컨퍼런스에 참여한다고 발표했습니다. James Rolke CEO는 2025년 3월 18일 화요일 오전 10:00 PT에 Dana Point, CA에서 예정된 대담에 참여할 예정입니다.
이 이벤트는 라이브 웹캐스트를 통해 접근 가능하며, 이후 Revelation의 웹사이트 www.RevBiosciences.com의 투자자 섹션에서 시청할 수 있습니다. 관심 있는 투자자는 Roth 대표를 통해 경영진과의 회의를 조정할 수 있습니다.
Revelation Biosciences (NASDAQ: REVB), une entreprise de sciences de la vie en phase clinique axée sur le rééquilibrage de l'inflammation pour optimiser la santé, a annoncé sa participation à la 37e Conférence Annuelle Roth. James Rolke, le Directeur Général de l'entreprise, participera à une discussion informelle prévue pour le mardi 18 mars 2025 à 10h00 PT à Dana Point, CA.
L'événement sera accessible via un webinaire en direct et sera ensuite disponible à la visualisation dans la section Investisseurs du site web de Revelation à l'adresse www.RevBiosciences.com. Les investisseurs intéressés peuvent organiser des réunions avec l'équipe de direction par l'intermédiaire de leurs représentants Roth.
Revelation Biosciences (NASDAQ: REVB), ein Unternehmen der Lebenswissenschaften in klinischer Phase, das sich auf die Wiederherstellung des Gleichgewichts von Entzündungen zur Optimierung der Gesundheit konzentriert, hat seine Teilnahme an der 37. jährlichen Roth-Konferenz angekündigt. James Rolke, der Geschäftsführer des Unternehmens, wird an einem informellen Gespräch teilnehmen, das für Dienstag, den 18. März 2025 um 10:00 Uhr PT in Dana Point, CA, geplant ist.
Die Veranstaltung wird über einen Live-Webcast zugänglich sein und anschließend in der Investoren-Sektion der Website von Revelation unter www.RevBiosciences.com verfügbar sein. Interessierte Investoren können über ihre Roth-Vertreter Meetings mit dem Management-Team vereinbaren.
- None.
- None.
The fireside chat will be webcast live here and available on our Investors section of Revelation Biosciences website, www.RevBiosciences.com, after the meeting.
Investors who wish to schedule a meeting with Revelation’s management during the conference should contact their Roth representative.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease.
For more information on Revelation, please visit www.RevBiosciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250313776522/en/
Company Contacts
Mike Porter
Investor Relations
Porter LeVay & Rose Inc.
Email: mike@plrinvest.com
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
Source: Revelation Biosciences, Inc.
FAQ
When is Revelation Biosciences (REVB) presenting at the Roth Conference 2025?
How can investors watch Revelation Biosciences' (REVB) Roth Conference presentation?
What is the focus area of Revelation Biosciences (REVB)?
How can investors schedule meetings with REVB management at the Roth Conference?
